title: [Heart rate and rate control :  Prognostic value in cardiovascular diseases].
abstract: Resting heart rate represents a cardiovascular risk indicator and an important target of therapy in chronic heart failure and potentially in coronary artery disease. Clinical and experimental evidence suggests that sustained elevation of heart rate - independent of the underlying trigger - plays a causal role in the pathogenesis of vascular disease. Results of the SHIFT trial support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in heart failure and confirm the role of heart rate as a risk factor for patients with severe left ventricular dysfunction. Results of the BEAUTIFUL trial show that patients with ischemic heart disease and a heart rate above 70 bpm exhibit an adverse prognosis concerning coronary events.
authors: Klinik für Innere Medizin III, Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland. florian.custodis@uks.eu
authors: F
authors: F
authors: Custodis
authors: J-C
authors: JC
authors: Reil
authors: U
authors: U
authors: Laufs
authors: M
authors: M
authors: Böhm
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control; D004562:Electrocardiography / Q000379:methods*; D006339:Heart Rate; D006801:Humans; D011379:Prognosis
chemical_list: D000889:Anti-Arrhythmia Agents